HK1115632A1 - Methods for the identification of zap-70 interacting molecules and for the purification of zap-70 - Google Patents
Methods for the identification of zap-70 interacting molecules and for the purification of zap-70Info
- Publication number
- HK1115632A1 HK1115632A1 HK08105785.0A HK08105785A HK1115632A1 HK 1115632 A1 HK1115632 A1 HK 1115632A1 HK 08105785 A HK08105785 A HK 08105785A HK 1115632 A1 HK1115632 A1 HK 1115632A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- aminopyrido
- zap
- pyrimidine ligand
- complex
- phosphorylated zap
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06011409A EP1862802B1 (en) | 2006-06-01 | 2006-06-01 | Methods for the identification of ZAP-70 interacting molecules and for the purification of ZAP-70 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1115632A1 true HK1115632A1 (en) | 2008-12-05 |
Family
ID=37075506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08105785.0A HK1115632A1 (en) | 2006-06-01 | 2008-05-23 | Methods for the identification of zap-70 interacting molecules and for the purification of zap-70 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20120178180A1 (da) |
EP (1) | EP1862802B1 (da) |
JP (1) | JP4987970B2 (da) |
CN (1) | CN101490557B (da) |
AT (1) | ATE417274T1 (da) |
AU (1) | AU2007267291B2 (da) |
CA (1) | CA2653760A1 (da) |
DE (1) | DE602006004196D1 (da) |
DK (1) | DK1862802T3 (da) |
ES (1) | ES2318616T3 (da) |
HK (1) | HK1115632A1 (da) |
WO (1) | WO2007137867A1 (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5181908B2 (ja) * | 2008-08-04 | 2013-04-10 | 株式会社島津製作所 | 質量分析データ解析装置 |
CA2758614A1 (en) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
US20120172385A1 (en) | 2009-09-11 | 2012-07-05 | Richard John Harrison | Ortho substituted pyrimidine compounds as jak inhibitors |
AR078675A1 (es) | 2009-10-20 | 2011-11-23 | Cellzome Ltd | Derivados de pirazolo[3,4-d]pirimidina inhibidores de jak quinasas, composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos para el tratamiento o profilaxis de trastornos inmunologicos, inflamatorios y autoinmunes. |
US20130131043A1 (en) | 2010-04-30 | 2013-05-23 | Richard John Harrison | Pyrazole compounds as jak inhibitors |
US20130281497A1 (en) * | 2010-05-21 | 2013-10-24 | University Of Florida Research Foundation, Inc. | Macrocyclic compounds and methods of treatment |
WO2012000970A1 (en) | 2010-07-01 | 2012-01-05 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
JP2013534233A (ja) | 2010-08-20 | 2013-09-02 | セルゾーム リミティッド | 選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体 |
AU2011328237A1 (en) | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
CA2843195A1 (en) | 2011-07-28 | 2013-01-31 | Cellzome Limited | Heterocyclyl pyrimidine analogues as jak inhibitors |
WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
EP2760863A1 (en) | 2011-09-20 | 2014-08-06 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
JP2015500862A (ja) | 2011-12-23 | 2015-01-08 | セルゾーム リミティッド | キナーゼ阻害剤としてのピリミジン−2,4−ジアミン誘導体 |
WO2013174895A1 (en) | 2012-05-24 | 2013-11-28 | Cellzome Limited | Heterocyclyl pyrimidine analogues as tyk2 inhibitors |
CN108088998B (zh) * | 2016-11-23 | 2019-12-27 | 四川大学华西医院 | 一种肺癌筛查试剂盒 |
CN113030359A (zh) * | 2021-01-28 | 2021-06-25 | 成都第一制药有限公司 | 一种益母草注射液中多种指标成分的检测方法及益母草注射液的质量控制方法 |
WO2022236319A1 (en) * | 2021-05-07 | 2022-11-10 | Enliven Therapeutics, Inc. | Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
US6685938B1 (en) * | 1998-05-29 | 2004-02-03 | The Scripps Research Institute | Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases |
AU781444B2 (en) * | 1999-12-22 | 2005-05-26 | Scripps Research Institute, The | Angiogenesis and vascular permeability modulators and inhibitors |
MXPA05009723A (es) * | 2003-03-10 | 2006-02-17 | Schering Corp | Analisis de ligando. |
JP5520433B2 (ja) * | 2004-01-21 | 2014-06-11 | エモリー ユニバーシティー | 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用 |
JP5058792B2 (ja) * | 2004-06-21 | 2012-10-24 | プロティオーム・サイエンシィズ・ピーエルシー | スクリーニング方法 |
EP1662259A1 (en) * | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
EP1894012A2 (en) * | 2005-05-18 | 2008-03-05 | Novartis AG | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
EP1891446B1 (en) * | 2005-06-14 | 2013-04-10 | Cellzome GmbH | Process for the identification of novel enzyme interacting compounds |
US20070105165A1 (en) * | 2005-11-04 | 2007-05-10 | Charles Goolsby | Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers |
EP2364702A3 (en) * | 2006-09-05 | 2012-01-25 | Emory University | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof |
WO2008110508A1 (en) * | 2007-03-09 | 2008-09-18 | Glaxo Group Limited | Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity |
-
2006
- 2006-06-01 AT AT06011409T patent/ATE417274T1/de active
- 2006-06-01 DE DE602006004196T patent/DE602006004196D1/de active Active
- 2006-06-01 EP EP06011409A patent/EP1862802B1/en not_active Not-in-force
- 2006-06-01 DK DK06011409T patent/DK1862802T3/da active
- 2006-06-01 ES ES06011409T patent/ES2318616T3/es active Active
-
2007
- 2007-06-01 CN CN2007800263541A patent/CN101490557B/zh not_active Expired - Fee Related
- 2007-06-01 JP JP2009512504A patent/JP4987970B2/ja not_active Expired - Fee Related
- 2007-06-01 AU AU2007267291A patent/AU2007267291B2/en not_active Ceased
- 2007-06-01 CA CA002653760A patent/CA2653760A1/en not_active Abandoned
- 2007-06-01 WO PCT/EP2007/004880 patent/WO2007137867A1/en active Application Filing
- 2007-06-01 US US12/302,711 patent/US20120178180A1/en not_active Abandoned
-
2008
- 2008-05-23 HK HK08105785.0A patent/HK1115632A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE602006004196D1 (de) | 2009-01-22 |
JP2009539081A (ja) | 2009-11-12 |
EP1862802B1 (en) | 2008-12-10 |
WO2007137867A1 (en) | 2007-12-06 |
ATE417274T1 (de) | 2008-12-15 |
CN101490557A (zh) | 2009-07-22 |
AU2007267291A1 (en) | 2007-12-06 |
CA2653760A1 (en) | 2007-12-06 |
EP1862802A1 (en) | 2007-12-05 |
US20120178180A1 (en) | 2012-07-12 |
ES2318616T3 (es) | 2009-05-01 |
CN101490557B (zh) | 2013-08-21 |
AU2007267291B2 (en) | 2013-09-12 |
JP4987970B2 (ja) | 2012-08-01 |
DK1862802T3 (da) | 2009-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1115632A1 (en) | Methods for the identification of zap-70 interacting molecules and for the purification of zap-70 | |
HK1111218A1 (en) | Methods for the identification of pi3k interacting molecules and for the purification of pi3k | |
Timm et al. | Assembly and purification of enzyme‐functionalized DNA origami structures | |
Dienhart et al. | The yeast Aac2 protein exists in physical association with the cytochrome bc 1-COX supercomplex and the TIM23 machinery | |
CN101675339B (zh) | 涉及细胞表面糖基化作用的方法 | |
WO2003039483A3 (en) | An enzyme-based system and sensor for measuring acetone | |
Wei et al. | Deep coverage proteomics identifies more low-abundance missing proteins in human testis tissue with Q-exactive HF mass spectrometer | |
WO2007050979A3 (en) | Real time nucleic acid detection in vivo using protein complementation | |
Salvi et al. | Motif analysis of phosphosites discloses a potential prominent role of the Golgi casein kinase (GCK) in the generation of human plasma phospho-proteome | |
WO2006065960A3 (en) | Cationic liposomes comprising a charge neutral compound and a cationic phospholipid | |
WO2009007719A3 (en) | Detection of micro-organisms based on their nad-dependent dna ligase activity | |
Pokhrel et al. | Probing the effect of mutations of asparagine 181 in the D1 subunit of photosystem II | |
WO2006020766A3 (en) | Point source diffusion cell activity assay apparatuses and methods | |
WO2006110748A3 (en) | Response gene to complement 32 (rgc-32) in disease | |
EP1243659A4 (en) | METHOD FOR DETECTION OF TARGET NUCLEOTIDE SEQUENCES | |
WO2010056681A3 (en) | Thyroid analyte detection and measurement | |
WO2005059163A3 (en) | Methods, compositions, and kits for analysis of enzyme activity in cells | |
WO2006119860A8 (de) | Zellkultursystem sowie verfahren zur kultivierung einer zellkultur | |
Baker et al. | Site-specific N-glycosylation characterization of windmill palm tree peroxidase using novel tools for analysis of plant glycopeptide mass spectrometry data | |
SG148027A1 (en) | Methods for identifying combinations of entities as therapeutics | |
Bulfer et al. | Crystal structure and functional analysis of homocitrate synthase, an essential enzyme in lysine biosynthesis | |
Gevaert et al. | Applications of diagonal chromatography for proteome‐wide characterization of protein modifications and activity‐based analyses | |
AU3326900A (en) | Ceramidase gene | |
Botzen et al. | Degradation of HNE-modified proteins–possible role of ubiquitin | |
GB0409775D0 (en) | Assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20140601 |